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correlate negatively with PV. Fibrinogen levels vary over timeImpact of albumin synthesis rate and the acute phase response
in synchrony with levels of other long-lived APPs, supportingin the dual regulation of fibrinogen levels in hemodialysis patients.
the hypothesis that fibrinogen is regulated in part as a compo-Background. Fibrinogen is a risk factor for cardiovascular
nent of the acute phase response and in part by factors thatdisease. It also is an acute phase protein (APP) and its plasma
increase albumin synthesis.concentration increases with inflammation. Fibrinogen synthe-
sis correlates with albumin synthesis in nephrotic patients and
in patients with an expanded plasma volume even when serum
albumin is normal and there is no inflammatory disease. The re-
Plasma fibrinogen is elevated in dialysis patients [1]lationships among albumin synthesis, the acute phase response
and correlates with vascular disease [2, 3] and graft lossand plasma fibrinogen levels in hemodialysis patients are un-
known. [4]. Fibrinogen is an important cardiovascular risk factor
Methods. In 74 hemodialysis patients, albumin synthesis, in the general patient population as well [5–8]. It is also
plasma volume (PV) and acute phase proteins (APPs) C-reac- a positive acute phase protein [9] and hence should betive protein (CRP), 1 acid glycoprotein (1 AG), ceruloplas-
increased in patients with inflammation [10, 11]. Fibrino-min (Cer), and interleukin 6 (IL-6) were measured in serum
gen synthesis is also regulated by factors other than theand fibrinogen in plasma, and the results analyzed by multiple
regression analysis. CRP, IL-6,1 AG, Cer and fibrinogen were acute phase response. Specifically, its synthesis correlates
measured monthly, which enabled us to determine whether positively with that of albumin in nephrotic patients [12]
changes in these APPs correlated with the levels of and variabil- and animals [13], conditions in which there is no relation-ity in plasma fibrinogen over time using a longitudinal modeling
ship between the acute phase response and regulation ofapproach. Length of follow-up for the 74 patients ranged from
fibrinogen gene expression. Indeed, in the nephrotic syn-3.25 to 67.5 months.
Results. Baseline fibrinogen (548.6 106. 4 mg/dL) was sig- drome, transcription of genes encoding a group of both
nificantly greater than levels reported for normal adults and positive and negative acute phase proteins is increased
correlated positively with albumin synthesis (P  0.001), age [12, 14] perhaps as part of a homeostatic mechanism that(P  0.001) and log CRP (P  0.002) and negatively with PV
defends plasma colloid osmotic pressure, suggesting that(P  0.001). Longitudinally, fibrinogen varied positively with
genes encoding both positive and negative acute phaselong-lived APPs, Cer and 1 AG, as well as the short-lived
APP, CRP. proteins may be regulated so that they are expressed co-
Conclusion. Plasma fibrinogen concentration is high in HD ordinately rather than reciprocally under this circum-
patients and directly correlates with increased albumin synthe-
stance. Fibrinogen synthesis also is increased in dialysissis rates and the serum levels of APPs. Fibrinogen levels also
patients with plasma volume expansion despite normal
serum albumin concentrations [15]. These observations
suggest the presence of a second mode of regulation of1 See Editorial by Goodship, p. 379.
fibrinogen gene expressions: perhaps it is regulated to
Key words: albumin synthesis, interleukin-6, plasma volume, acute
maintain plasma total protein concentration or colloidphase, C-reactive protein, ceruloplasmin, 1 acid glycoprotein, nutri-
tion, body mass index, nPCR. osmotic pressure.
We measured the rate of albumin turnover kinetically
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of the correlation between albumin synthetic rate and 4.62 years). Forty-two patients were African American,
and 29 patients had diabetes mellitus. In the other 45,plasma fibrinogen levels measured simultaneously. We
also obtained blood sequentially to establish the longitu- renal failure was caused by hypertension in 19 patients,
11 patients had glomerulonephritis, three had adult poly-dinal interrelationship among various positive and nega-
tive acute phase proteins. We performed this analysis to cystic kidney disease, one had systemic lupus, one had
chronic pyelonephritis, one had acute renal failure with-establish parameters associated with fibrinogen levels at
baseline and as the levels of acute phase proteins varied out recovery, one had analgesic nephropathy, two had
had bilateral nephrectomy, one had analgesic nephropa-longitudinally.
thy, one had hereditary nephritis, and the remainder had
renal failure of uncertain etiology. Thirty-eight patients
METHODS
had a subcutaneous polytetrafluoroethylene (PTFE)
Patient selection graft, 28 had arteriovenous (AV) fistulas and eight had
a tunneled transcutaneous dialysis catheter access.The individual Institutional Review Boards at each
institution approved the protocol and informed consent Twenty-seven patients were dialyzed using an F80 (Fre-
senius Medical Care North America, Lexington, MA,was obtained from each patient. Seventy-four patients
enrolled in the National Institutes of Health HEMO USA), 28 using an F 8 (Fresenius Medical Care North
America) one with an F 6 (Fresenius Medical Care NorthStudy at the University of California Davis (Sacramento,
CA), at Beth Israel Medical Center (New York, NY), America), six using a CA210 dialyzer (Baxter Healthcare
Corporation, Deerfield, IL, USA), seven using a CT190Gand at Emory University (Atlanta, GA) were recruited
to participate in a longitudinal study of the relationship dialyzer (Baxter Healthcare), three using CT 190, (Bax-
ter Healthcare) dialyzer. One patient was dialyzed withbetween the levels of acute phase proteins and serum
albumin concentration. All patients who had been ran- a Filtral 20 dialyzer (Hospal, Boca Raton, FL, USA). In
seven patients dialyzers were not reprocessed. Thirty-domized into one of the four HEMO treatment groups
were eligible for enrollment in this study. Inclusion crite- five were subjected to reuse with bleach/formaldehyde,
26 with hot citric acid and six with Renalin. All dialysisria for the HEMO Study require that the patient be
between 18 and 80 years of age, receive in-center hemo- was performed using bicarbonate-based dialysate at a
delivered bicarbonate concentration of 39 mEq/L. Sincedialysis three times per week, and have been on dialysis
for at least three months. Exclusion criteria include a dialyzer flux was a randomization variable, analysis of
the effects of dialyzer type and of the effects of reuseurine urea clearance of 1.5 mL/min/35 L urea volume,
the presence of serious comorbid medical conditions such was not permitted.
as active malignancies requiring chemotherapy or radia-
Laboratory methodstion therapy, treated class IV congestive heart failure,
unstable angina pectoris, symptomatic AIDS, active sys- Serum albumin was measured using bromcresol green.
All other proteins [transferrin, ceruloplasmin and  1temic infections such as tuberculosis or systemic fungal
infection, chronic pulmonary disease requiring supple- acid glycoprotein (1 AG)] were measured initially and
then weekly by rate nephelometry using a Beckman Ar-mental oxygen, and cirrhosis with encephalopathy or
abnormal prothombin time; and scheduled living donor ray automated nephelometer [18]. Interleukin-6 (IL-6)
was measured by enzyme-linked immunosorbent assaytransplant within the period of the study. Additionally,
we required that the patients be able and willing to come (ELISA; Hemagen Diagnostics, Inc., Waltham, MA,
USA). All nephelometric measurements were made into the Clinical Research Center or nuclear medicine unit
on a non-dialysis day for injection of [125]I human albumin duplicate in each of two optical systems. Fibrinogen was
measured from citrated plasma obtained pre-dialysisand for collection of the initial blood samples.
During the initial six weeks following enrollment albu- [with an inter-assay coefficient of variation (CV), 5.7%;
intra-assay, coefficient of variation 2.5%]. All other pro-min turnover rate was measured as described [16, 17].
Briefly, 10 Ci of [125]I human albumin was injected as teins were measured in serum. All measurements were
made in duplicate. The average of these values was useda bolus and its disappearance from plasma was measured
over a six week period. Albumin turnover rate, which for calculations. The intra-assay CV for albumin was
0.22%, with an inter-assay ranging from 2.42 to 3.16%at steady state is equal to the rate of albumin synthesis
over that six week period could then be modeled kinet- over the usable range of the assay. The intra-assay CV
for 1 acid glycoprotein was 0.14%, with an inter-assayically [16, 17]. This value is referred to as the albumin
synthesis rate. Plasma volume at the time of initial injec- CV ranging from 3.07 to 5.50% over the usable range
of the assay. The intra-assay CV for ceruloplasmin wastion of [125]I human albumin was established from isotope
dilution calculation. 0.27%, with an inter-assay CV ranging from 4.44 to 9.18%
over the usable range of the assay. The intra-assay CVThe 74 patients had been on dialysis for a mean time
of 5.63  3.19 years (range 0.62 to 19.94 years; median for transferrin ranged from 0.026 to 0.07%, with an inter-
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Table 1. Description of variables
Variable Mean SD Range Median Minimum Maximum
Fibrinogen mg/kg 549 106 495 542 309 804
BMI kg/m2 23.8 4.53 23.5 23.3 12.0 35.5
PV % 4.70 1.34 7.49 4.62 2.44 9.90
Albumin g/dL 4.09 0.316 2.28 4.15 2.50 4.77
Ceruloplasmin mg/dL 38.4 7.93 35.1 37.8 21.4 56.5
Transferrin mg/dL 179 29.6 127 180 114 241
1 AG mg/dL 116 33.1 178 113 60.6 239
CRP mg/dL 0.966 0.927 4.23 0.553 0.0750 4.30
IL-6 10.0 13.0 94.5 6.41 0 94.5
nPCR g/kg/day 1.02 0.312 1.57 0.927 0.521 2.09
Albumin synthesis g/1.73 m2/day 14.4 3.62 18.2 14.4 5.65 23.9
Age years 57.2 14.3 62 59 19 81
Description of the cross sectional data at the time of initial injection of 125I albumin [Plasma volume (PV % body weight)] and the average values for other
variables during the initial 6 weeks following that injection. Abbreviations are: SD, standard deviation; BMI, body mass index; 1 AG, 1 acid glycoprotein; CRP,
C-reactive protein; IL-6, interleukin-6; nPCR, normalized protein catabolic rate.
Table 3. Longitudinal linear mixed effects model for fibrinogenTable 2. Cross-sectional multiple linear regression model
for fibrinogen
Fixed effects Estimate SD t value P value
Coefficients Estimate SD t value P value
Intercept 72.895 51.351 1.4196 0.1559
1 AG mg/dL 1.336 0.154 8.6682 0.0001Intercept 526.332 63.013 8.353 0.001
log. CRP 33.023 9.981 3.309 0.002 Cer mg/dL 2.462 0.714 3.4475 0.0006
log. CRP 6.883 1.755 3.9209 0.0001PV % body weight 46.202 7.884 5.860 0.001
Albumin synthesis g/1.73 m2/day 11.360 3.045 3.730 0.001 Age years 1.835 0.515 3.5627 0.0007
BMI kg/m2 6.634 1.655 4.0077 0.0001Male gender 47.425 18.353 2.584 0.012
Age years 2.305 0.656 3.512 0.001 Longitudinal variables associated with plasma fibrinogen concentration over
Access time. Abbreviations are: 1 AG, 1 acid glycoprotein; Cer, ceruloplasmin; CRP,
Graft 16.053 20.352 0.789 0.433 C-reactive protein. Baseline variables associated with plasma fibrinogen concen-
Transcutaneous 73.821 31.205 2.366 0.021 tration over time are age and BMI.
Model predicting baseline fibrinogen concentration during the baseline 6 week
period. Cross-sectional values of variables (fibrinogen, albumin, albumin synthe-
sis rate) are defined as in reference 18, that is, six-week averages after injection
of 10 Ci [125]I albumin to measure albumin synthesis rate. Vascular access is nous graft, or transcutaneous access), ethnicity (blackevaluated as the presence of a PTFE graft or a transcutaneous access (catheter)
versus arteriovenous fistula as control. Residual standard error, 74.3 on 62 de- vs. non-black), gender, and the presence or absence of
grees of freedom; multiple R 2, 0.553; F-statistic, 10.9 on 7 and 62 degrees of diabetes. There were insufficient numbers of patientsfreedom; the P value is 6.58e-009. A negative coefficient for gender means
women, on average, have higher fibrinogen levels than men. having other causes of renal failure to perform meaning-
ful analysis based on other causes of renal failure. All
non-black patients were combined for statistical analysis
because of the low numbers of other ethnic groups. Vari-
assay CV ranging from 2.56 to 4.38%. Normalized protein ables were selected using an all subsets regression ap-
catabolic rate (nPCR) was measured monthly using a proach with both adjusted coefficient of determination
double pool method of urea kinetic analysis [19]. and Cp criterion. Though we started with 74 patients,
Summary of the cross sectional data obtained during only 70 were able to be used for the cross-sectional analy-
the six week period when albumin synthesis was mea- sis due to a lack of available baseline fibrinogen data for
sured are reported in Table 1. three patients and available baseline nPCR data for a
fourth patient.
Statistical methods The longitudinal linear mixed effects model used all
Two models for fibrinogen were generated, one using 74 patients and followed the same approach as previously
multiple linear regression for a cross-sectional (baseline) described [20, 21], including use of the assumption of
model (Table 2) and the other using linear mixed effects autocorrelated within-patient errors and variable selec-
modeling for a longitudinal model of fibrinogen levels tion by Akaike’s information criterion (AIC). Available
over time (Table 3). For the cross-sectional model, we time-dependent protein variables included albumin, CRP,
examined a number of potential predictors including base- 1 AG, ceruloplasmin, transferrin, nPCR, and IL-6.
line albumin, C-reactive protein (CRP), 1 AG, cerulo- Available baseline variables included BMI, age, vascular
plasmin, transferrin, nPCR, and IL-6 (initial six-week access, ethnicity (black vs. non-black), gender, and pres-
average of each), initial plasma volume percent (ex- ence or absence of diabetes. The reported coefficients of
pressed as % body weight), albumin synthesis rate, body variation (CV) were calculated in the following fashion
using the longitudinal data for each patient. First, formass index (BMI), age, vascular access (fistula, arteriove-
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Fig. 1. (A) Relationship between plasma fibrinogen concentration and C-reactive protein (CRP) level following log transformation (R  0.272;
P  0.22). (B) Relationship between plasma fibrinogen concentration and ceruloplasmin during the baseline cross-sectional measurement (R 
0.317; P  0.007).
each protein, taking the standard deviation of the re-
peated measurements of that protein for the patient gen-
erated a patient-level coefficient of variation dividing by
the mean of these repeated measurements. This would
be atypical for a cross-sectional study, where the observa-
tions used for generating both the numerator (that is,
the standard deviation) and the denominator (that is,
the mean) is independent. Second, the overall estimate
of the mean CV reported in the paper was calculated
by taking an unweighted average of these patient-level
CV values within a given protein.
All models were fit using S-Plus 6.0 (Insightful Corpo-
ration, 2001, Seattle, WA, USA).
RESULTS Fig. 2. Relationship between plasma fibrinogen concentration and
plasma volume (% body weight) during baseline cross sectional mea-Plasma fibrinogen levels were significantly higher in surement (R  0.516; P  0.001).
dialysis patients (548.6  106. 4 mg/dL), compared to
values of 313  55.1 mg/dL for normal adults published
by de Sain-van der Velden et al [12] (P  0.001) or by
brinogen level correlated positively with CRP (after log
Balagopal et al for lean (185 6 mg/dL) or obese (239 transformation) P  0.002, albumin synthesis rate (P 
7 mg/dL) adults [22]. Basal fibrinogen level (average value 0.001), age (P  0.001) and female gender (plasma fi-
during the initial study of albumin synthesis, that is, the brinogen levels were greater in women), and negatively
first six weeks of observation) correlated positively with with plasma volume (P 0.001) and vascular access type
average value for log CRP (P  0.022; Fig. 1A) and (the presence of a transcutaneous vascular access; Table 2).
ceruloplasmin (P  0.0071; Fig. 1B) and negatively with There was no correlation with fibrinogen levels and eth-
plasma volume (P 0.001; Fig. 2) by univariate analysis. nicity or the presence of diabetes and prior or present
There was no significant difference between the average history of smoking. The two most powerful predictors
plasma albumin concentration averaged over the entire of fibrinogen were PV and albumin synthesis rate, collec-
period of the synthesis study and the initial serum albu- tively contributing an r 2 of 0.337 to the total relationship
min concentration. Therefore, the average serum albu- (Fig. 3). Results in the surface plot of plasma fibrinogen
min value is presented. Albumin synthesis rate, plasma versus PV and albumin synthesis rate (Fig. 3) demon-
and total albumin masses are normalized by body surface strate there is linearity of relationships between plasma
area and plasma volume expressed as the percent body fibrinogen and either of the two measured variables and
weight, respectively. that the effects of these two predictors are additive, that
is, there is no interaction.By multiple linear regression analysis, the basal fi-
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erosclerotic disease [24, 25], carotid artery stenosis [26]
and death among patients who have sustained myocar-
dial infarction [27]. Fibrinogen levels are consistently
elevated in patients with chronic renal failure [28] and
represent an independent risk factor for coronary artery
disease [29].
Fibrinogen is a positive acute phase protein [30] pro-
viding an explanation for why plasma fibrinogen was
associated both with CRP levels and with levels of long-
lived, acute phase proteins. While levels of inflammatory
markers have been shown to be high in dialysis patients
[31–33], their levels vary temporally and the longer-lived
APPs can even be used to predict future changes in serum
albumin concentration [20, 21]. In the present analysis,
we found that high levels of acute phase proteins were
associated with concurrent fibrinogen levels when ana-
lyzed longitudinally and also correlated positively with
plasma fibrinogen levels in addition to the cross-sectional
association described at baseline. These results suggest
that variations in the plasma fibrinogen concentration as
well as the absolute level of fibrinogen at any point in
time are part of the inflammatory response. For these rea-
sons, we conclude that inflammation is one factor leading
to high plasma fibrinogen levels in dialysis patients and
in part explains the relationship between fibrinogen lev-
Fig. 3. Relationship between plasma fibrinogen concentration and els and cardiovascular risk in this population [6–8, 34].
both albumin synthesis in g/1.73 m2/day and plasma volume in percent
Inflammation alone, however, does not appear to be thebody weight (PV%) at the time of the initial injection of [125]I albumin.
Fibrinogen  603  (13.14 * albumin synthesis/1.73 m2)  [52.67 * sole factor regulating fibrinogen levels in dialysis patients.
PV(%)]; PV, P  0.0001, r 2  0.1984; albumin synthesis, P  0.0001, In patients with the nephrotic syndrome the rates of
r 2  0.1586.
both albumin and fibrinogen synthesis are increased in
parallel with one another [12] and are both regulated at
the level of gene transcription in rodent models [13, 14].
A reduction in proteinuria resulting from dietary proteinLongitudinally plasma fibrinogen concentration varied
restriction causes an increase in serum albumin levelsover time (Fig. 4). The results of the longitudinal, linear,
[35, 36]. This occurs despite a decrease in albumin syn-mixed-effects model for fibrinogen showed that the con-
thesis [35–37]. Notably, there also is a decrease in thecentration of fibrinogen at any time was associated with
rate of fibrinogen synthesis [37]. These findings suggestthe prevalent values of log CRP, 1 AG, ceruloplasmin,
there is a coordinated, positive relationship in expressionas well as with baseline values of BMI and age (Table
of both the fibrinogen and albumin genes in the nephrotic3). Interestingly, the variability of fibrinogen (relative to
syndrome, in which expression of both genes is aug-its mean value) was similar to that of other long-lived
mented when colloid osmotic pressure or protein concen-acute phase proteins 1 AG and ceruloplasmin and sig-
tration decreases, and expression of both genes is de-nificantly less than that of IL-6 and CRP. A similar result
creased when plasma protein concentration returnsexists between the serum albumin concentration and
toward normal. To explain this coordinated response,these same longer-lived APPs [20]. The variability of
we have suggested that synthesis of a group of proteins,plasma fibrinogen was significantly greater than that of
including fibrinogen and albumin, respond to changes inserum albumin or transferrin (Fig. 5).
or act to support plasma protein concentration or colloid
osmotic pressure [13, 14]. In this case, the coordinated
DISCUSSION transcriptional response is independent of the acute
Plasma fibrinogen levels are highly associated with the phase response. This is consistent with the observations
presence of abnormalities of the cardiovascular system that other negative acute phase proteins, notably trans-
including left ventricular hypertrophy, arterial stiffness, ferrin [13, 14, 38, 39] and apo A-I [13, 14, 40] and the
or systolic myocardial dysfunction. This relationship is positive acute phase protein lipoprotein(a) [Lp(a)] [41]
independent of covariates including renal dysfunction have and increased rate of synthesis in conditions associ-
ated with decreased plasma colloid osmotic pressure[23] and also predicts the incidence and severity of ath-
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Fig. 4. Temporal variation in serum fibrinogen concentration (; weeks vs. fibrinogen g/L), CRP concentration (; weeks vs. CRP mg/dL),
albumin (• ; weeks vs. albumin g/dL) and 1 acid glycoprotein (; weeks vs 1 AG g/L) in four consecutive hemodialysis patients in whom CRP
changed by at least one order of magnitude during the period of observation. Units were scaled to show protein levels in similar ranges.
(such as, the nephrotic syndrome and hereditary anal- albumin synthesis in this cohort of patients [16]. The
relevance of our explanation to the present study is thatbuminemia when there is no inflammation).
the plasma volume expansion of hemodialysis patientsPlasma volume expansion if unopposed by an increase
may be another situation that would reduce albuminin the mass of plasma proteins also should lead, like the
concentration and lead to a compensatory increase innephrotic syndrome, to a reduction in plasma protein
the rate of both albumin and fibrinogen synthesis toconcentration or colloid osmotic pressure. However, it
compensate for this action.appears that at least in some circumstances plasma vol-
The present association between plasma fibrinogenume expansion is associated with an increased rate of
levels and the rate of albumin synthesis is consistentsynthesis of some plasma proteins, suggesting a response
with a coordinated response that links transcriptionalthat is similar at least in this regard, to what occurs when
responses of the two proteins. We believe the reason
plasma proteins are lost into the urine. that fibrinogen levels are so high in dialysis patients is
Plasma volume expansion in response to increasing that there are two separate independent regulatory
altitude has been shown to increase the rate of synthesis mechanisms that combine to cause an increased fibrino-
of both albumin and fibrinogen [42]. Similarly albumin gen synthetic rate, inflammation and stimulation of syn-
and fibrinogen synthesis are increased in hemodialysis thesis by one or more of the factors that raise albumin
patients with normal serum albumin concentration but synthesis. The association reported in our current study
expanded plasma volumes [15]. We have reported that is that between plasma volume expansion and albumin
synthetic rate.plasma volume was highly associated with the rate of
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